Mitochon Pharmaceuticals

About:

Mitochon Pharmaceuticals is a start-up biotech company.

Website: http://www.mitochonpharma.com/

Top Investors: Ben Franklin Technology Partners of Southeastern Pennsylvania

Description:

Mitochon Pharmaceuticals is a start-up biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Their development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies. Mitochon is led by a team of industry executives with over 80-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of devastating diseases.

Total Funding Amount:

$2.33M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Radnor, Pennsylvania, United States

Founded Date:

2014-01-01

Founders:

John G. Geisler, Robert Alonso

Number of Employees:

1-10

Last Funding Date:

2016-05-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai